Send to

Choose Destination
Dermatol Ther (Heidelb). 2017 Sep;7(3):281-292. doi: 10.1007/s13555-017-0187-0. Epub 2017 Jun 21.

Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials.

Author information

Department of Dermatology, University of California San Francisco, San Francisco, CA, USA.
University of California Los Angeles, Los Angeles, CA, USA.
Department of Dermatology, University of California San Francisco, San Francisco, CA, USA.



Interleukin (IL)-23 inhibitors are a new class of biologics currently undergoing clinical trials for the treatment of moderate-to-severe psoriasis. Phase III studies of guselkumab, an IL-23 receptor monoclonal antibody, are currently underway.


We summarize the available phase III results to date, establishing the efficacy and safety of guselkumab in patients with moderate-to-severe plaque psoriasis.


Currently, there are available data of up to 48 weeks from two Phase III, multicenter, randomized, double-blind, placebo- and comparator-controlled clinical trials, VOYAGE 1 and VOYAGE 2. At week 16, the proportion of patients attaining at least a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) was 73.3% in VOYAGE 1 and 70.0% in VOYAGE 2. Guselkumab remained efficacious through 48 weeks of treatment. Guselkumab maintained a satisfactory safety profile with the most frequently reported adverse events being nasopharyngitis, headache, and upper respiratory tract infection.


Phase III trials of Guselkumab suggest a favorable efficacy and safety profile of this novel drug. Although further studies are needed to assess long-term safety and efficacy, based on the results to date, guselkumab appears to be a promising therapeutic option for moderate-to-severe plaque-type psoriasis.


Anti-interleukin-23; Biologics; Guselkumab; Phase III; Psoriasis; VOYAGE

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center